Walter P Maksymowych Selected Research

Interleukin-17 (Interleukin 17)

10/2023	Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
1/2023	Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
9/2022	Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
1/2022	Improving the design of RCTs in non-radiographic axial spondyloarthritis.
1/2022	A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
1/2021	Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis.
1/2020	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
12/2018	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Walter P Maksymowych Research Topics

Disease

67	Ankylosing Spondylitis 04/2024 - 03/2002
50	Inflammation (Inflammations) 05/2024 - 11/2002
36	Axial Spondyloarthritis 02/2024 - 02/2011
30	Rheumatoid Arthritis 12/2023 - 03/2002
18	Non-Radiographic Axial Spondyloarthritis 05/2024 - 06/2013
18	Arthritis (Polyarthritis) 01/2020 - 08/2002
11	Necrosis 01/2022 - 09/2002
9	Sacroiliitis 09/2022 - 06/2003
9	Psoriatic Arthritis 01/2022 - 07/2002
8	Back Pain (Backache) 03/2014 - 02/2004
6	Pain (Aches) 05/2024 - 10/2005
6	Infections 01/2022 - 05/2002
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2024 - 12/2007
5	Osteoarthritis 12/2023 - 10/2012
5	Ankylosis 01/2022 - 09/2002
4	Osteoporosis 08/2013 - 10/2007
3	Spondylarthropathies 05/2024 - 10/2002
3	Nasopharyngitis 01/2023 - 12/2018
3	Joint Diseases (Joint Disease) 09/2015 - 05/2002
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2009 - 03/2006
2	Opportunistic Infections (Opportunistic Infection) 05/2024 - 01/2022
2	Neoplasms (Cancer) 05/2024 - 01/2022
2	Metaplasia 01/2022 - 04/2014
2	Crohn Disease (Crohn's Disease) 12/2018 - 04/2008
2	Hip Osteoarthritis (Coxarthrosis) 01/2018 - 07/2007
2	Arthralgia (Joint Pain) 04/2016 - 03/2002
2	Iritis 02/2016 - 02/2016
2	Rheumatic Diseases (Rheumatism) 04/2013 - 04/2011
2	Synovitis 09/2011 - 09/2002
2	Edema (Dropsy) 09/2011 - 10/2010
2	Disease Susceptibility (Diathesis) 02/2010 - 11/2002
2	Disease Progression 02/2010 - 11/2002
2	Palindromic rheumatism 07/2006 - 11/2002
1	Oral Candidiasis (Thrush) 01/2023
1	Pharyngitis (Sore Throat) 01/2023
1	Mycoses (Diseases, Fungus) 01/2023
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2023
1	Headache (Headaches) 01/2023
1	Tuberculosis (Tuberculoses) 01/2023

Drug/Important Bio-Agent (IBA)

25	Biomarkers (Surrogate Marker)IBA 04/2024 - 06/2005
19	C-Reactive ProteinIBA 04/2024 - 10/2005
15	Adalimumab (Humira)FDA Link 04/2024 - 12/2007
13	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2020 - 03/2002
11	Etanercept (Enbrel)FDA Link 02/2024 - 06/2003
11	Infliximab (Remicade)FDA Link 01/2023 - 05/2002
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 05/2002
10	Tumor Necrosis Factor InhibitorsIBA 11/2022 - 04/2014
9	Antirheumatic Agents (DMARD)IBA 01/2022 - 09/2015
9	Proteins (Proteins, Gene)FDA Link 12/2020 - 12/2006
8	Interleukin-17 (Interleukin 17)IBA 10/2023 - 12/2018
7	ixekizumabIBA 04/2024 - 12/2018
7	Certolizumab Pegol FDA Link 09/2022 - 01/2017
7	CytokinesIBA 01/2022 - 10/2002
6	upadacitinibIBA 05/2024 - 12/2019
6	Monoclonal AntibodiesIBA 01/2021 - 12/2007
5	Sulfasalazine (Azulfidine)FDA LinkGeneric 10/2019 - 09/2002
4	InterleukinsIBA 10/2023 - 02/2010
4	GLPG0634IBA 01/2022 - 12/2018
4	Interleukin-23 (Interleukin 23)IBA 01/2022 - 04/2008
4	HLA-B27 Antigen (HLA B27 Antigen)IBA 10/2021 - 06/2003
4	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 04/2012 - 07/2009
3	tofacitinibIBA 08/2023 - 01/2018
3	Janus KinasesIBA 01/2022 - 09/2018
3	HLA-B Antigens (HLA-B)IBA 11/2019 - 07/2013
3	VimentinIBA 01/2019 - 04/2013
3	Metalloproteases (Metalloproteinases)IBA 01/2019 - 12/2007
3	AutoantibodiesIBA 01/2019 - 09/2015
3	AntibodiesIBA 02/2016 - 07/2006
3	Fenofibrate (CiL)FDA LinkGeneric 01/2013 - 01/2009
2	bimekizumabIBA 10/2023 - 01/2023
2	golimumab FDA Link 01/2023 - 01/2022
2	Janus Kinase InhibitorsIBA 01/2022 - 01/2021
2	Phosphotransferases (Kinase)IBA 01/2021 - 12/2020
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2019 - 07/2015
2	Endothelial Growth FactorsIBA 01/2019 - 07/2015
2	AminopeptidasesIBA 09/2018 - 07/2013
2	Leflunomide (Arava)FDA LinkGeneric 07/2017 - 06/2005
2	Anti-Citrullinated Protein AntibodiesIBA 04/2016 - 07/2006
2	Rheumatoid FactorIBA 04/2016 - 11/2002
2	EnzymesIBA 02/2016 - 08/2013
2	GlucocorticoidsIBA 02/2016 - 02/2016
2	Protein Isoforms (Isoforms)IBA 04/2014 - 08/2007
2	Collagen Type II (Type II Collagen)IBA 01/2013 - 08/2002
2	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 02/2010 - 01/2009
2	Diphosphonates (Bisphosphonates)IBA 02/2008 - 03/2003
2	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 06/2007 - 10/2004
2	Calcineurin InhibitorsIBA 03/2006 - 08/2002
2	Methotrexate (Mexate)FDA LinkGeneric 06/2005 - 06/2003
2	Pamidronate (Aredia)FDA LinkGeneric 12/2004 - 03/2002
1	Matrix Metalloproteinases (MMPs)IBA 12/2023
1	Immunoglobulin G (IgG)IBA 10/2023
1	omega-Chloroacetophenone (Mace)IBA 01/2023
1	LipopolysaccharidesIBA 01/2023
1	InterferonsIBA 01/2022

Therapy/Procedure

40	Therapeutics 05/2024 - 05/2002
3	Biological Therapy 01/2018 - 10/2013
2	Contraindications 12/2019 - 06/2013
2	Arthroplasty 02/2016 - 02/2016
2	Physical Therapy Modalities (Physical Therapy Technique) 02/2016 - 02/2016
1	Drug Therapy (Chemotherapy) 01/2022